{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:39:07Z","timestamp":1763415547249},"reference-count":78,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Many severe illnesses with a systemic impact may cause activation of coagulation. While systemic activation of coagulation leads to a coagulopathy that follows many common activation pathways and failure of endogenous regulatory anticoagulant systems, underlying conditions may utilize distinctive pathogenetic routes and may vary in clinical manifestations of the coagulopathy. The coagulation derangement associated with hematological malignancies and the coagulopathy of coronavirus disease 2019 (COVID-19) clearly demonstrate such differences. Malignancies are associated with venous thromboembolism due to the biological effect of malignant cells, frequent medical interventions, or the presence of indwelling vascular catheters. The underlying pathogenesis of cancer-associated coagulopathy relies on tissue factor-mediated activation of coagulation, cytokine-controlled defective anticoagulant pathways, fibrinolytic changes, and dysfunctional endothelium. There is an additional risk caused by anti-cancer agents including chemotherapy and immunotherapy. The underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example, by vascular endothelial growth factor inhibition). In addition, individual anti-cancer agents may have specific prothrombotic effects. One of the remarkable features of severe COVID-19 infections is a coagulopathy that mimics but is not identical to the disseminated intravascular coagulation and thrombotic microangiopathy and has been identified as a strong marker for an adverse outcome. Severe COVID-19 infections cause inflammation-induced changes in coagulation in combination with severe endothelial cell injury. This coagulopathy likely contributes to pulmonary microvascular thrombosis, bronchoalveolar fibrin deposition (which is a hallmark of acute respiratory distress syndrome) and venous thromboembolic complications.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000571","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T14:03:32Z","timestamp":1622815412000},"page":"e571","source":"Crossref","is-referenced-by-count":15,"title":["Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19"],"prefix":"10.1002","volume":"5","author":[{"given":"Marcel","family":"Levi","sequence":"first","affiliation":[{"name":"Department of Medicine and Cardiometabolic Programme-NIHR UCLH\/UCL BRC, University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"Department of Vascular Medicine, Amsterdam University Medical Center (location Academic Medical Center), Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"R1-20231201","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2017-10-804096","article-title":"How I treat disseminated intravascular coagulation.","volume":"131","author":"Levi","year":"2018","journal-title":"Blood"},{"key":"R3-20231201","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM199908193410807","article-title":"Disseminated intravascular coagulation.","volume":"341","author":"Levi","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-20231201","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/01.CCM.0000281468.94108.4B","article-title":"Disseminated intravascular coagulation.","volume":"35","author":"Levi","year":"2007","journal-title":"Crit Care Med"},{"key":"R5-20231201","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1111\/jth.14946","article-title":"Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis.","volume":"18","author":"Squizzato","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R6-20231201","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.thromres.2019.04.030","article-title":"The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases.","volume":"179","author":"Iba","year":"2019","journal-title":"Thromb Res"},{"key":"R7-20231201","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0028-1087126","article-title":"Diffuse intravascular coagulation in liver disease?","volume":"4","author":"Straub","year":"1977","journal-title":"Semin Thromb Hemost"},{"key":"R8-20231201","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-0030-1254045","article-title":"Disseminated intravascular coagulation: a disease-specific approach.","volume":"36","author":"Levi","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"R10-20231201","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0039-1687890","article-title":"Disseminated intravascular coagulation in cancer: an update.","volume":"45","author":"Levi","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"suppl 2","key":"R11-20231201","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0049-3848(14)50012-6","article-title":"Cancer-related coagulopathies.","volume":"133","author":"Levi","year":"2014","journal-title":"Thromb Res"},{"key":"R12-20231201","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19.","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"R13-20231201","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13054-020-03077-0","article-title":"The unique characteristics of COVID-19 coagulopathy.","volume":"24","author":"Iba","year":"2020","journal-title":"Crit Care"},{"key":"R14-20231201","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","article-title":"Coagulopathy of coronavirus disease 2019.","volume":"48","author":"Iba","year":"2020","journal-title":"Crit Care Med"},{"key":"R15-20231201","first-page":"6S8","article-title":"Cancer and thrombosis: new insights to an old problem.","volume":"45","author":"Leiva","year":"2020","journal-title":"J Med Vasc"},{"issue":"suppl 1","key":"R16-20231201","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0049-3848(20)30391-1","article-title":"An overview of thrombotic complications of old and new anticancer drugs.","volume":"191","author":"Levi","year":"2020","journal-title":"Thromb Res"},{"key":"R17-20231201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects.","volume":"11","author":"Falanga","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R18-20231201","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer.","volume":"41","author":"Falanga","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"R19-20231201","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-2001-18865","article-title":"Disseminated intravascular coagulation in acute leukemia.","volume":"27","author":"Barbui","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"R20-20231201","first-page":"CD008562","article-title":"Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.","volume":"2015","author":"Marti-Carvajal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20231201","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0030-1254048","article-title":"Disseminated intravascular coagulation in hematologic malignancies.","volume":"36","author":"Franchini","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"R22-20231201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited.","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R23-20231201","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"R24-20231201","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1034\/j.1600-0609.2000.09001.x","article-title":"All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia.","volume":"64","author":"Visani","year":"2000","journal-title":"Eur J Haematol"},{"key":"R25-20231201","doi-asserted-by":"crossref","first-page":"V187","DOI":"10.1016\/S0049-3848(01)00235-3","article-title":"Venous thromboembolism and occult malignancy.","volume":"102","author":"Otten","year":"2001","journal-title":"Thromb Res"},{"key":"R26-20231201","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"R27-20231201","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies.","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R28-20231201","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"R29-20231201","first-page":"495","article-title":"Thrombotic microangiopathy following bone marrow transplantation.","volume":"14","author":"Pettitt","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"R30-20231201","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs.","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R31-20231201","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"R32-20231201","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.10847","article-title":"A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.","volume":"95","author":"Desai","year":"2002","journal-title":"Cancer"},{"key":"R33-20231201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"key":"R34-20231201","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality.","volume":"4","author":"Schoen","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"R35-20231201","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2002.20.6.1657","article-title":"Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.","volume":"20","author":"Kuenen","year":"2002","journal-title":"J Clin Oncol"},{"key":"R36-20231201","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0041-1722863","article-title":"Advances in the management of cancer-associated thrombosis.","volume":"47","author":"Dhami","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"R37-20231201","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-994916","article-title":"Thrombotic complications of central venous catheters in cancer patients.","volume":"25","author":"Bona","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"R38-20231201","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1200\/JCO.2002.11.135","article-title":"Complication rates among cancer patients with peripherally inserted central catheters.","volume":"20","author":"Walshe","year":"2002","journal-title":"J Clin Oncol"},{"key":"R39-20231201","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.V73.7.2018.2018","article-title":"Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.","volume":"73","author":"Holler","year":"1989","journal-title":"Blood"},{"key":"R40-20231201","first-page":"499","article-title":"von Willebrand factor as a marker of endothelial cell activation following BMT.","volume":"10","author":"Collins","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"R41-20231201","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00135874","article-title":"Chemotherapy enhances endothelial cell reactivity to platelets.","volume":"8","author":"Bertomeu","year":"1990","journal-title":"Clin Exp Metastasis"},{"key":"R42-20231201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.20020077","article-title":"The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.","volume":"196","author":"Conway","year":"2002","journal-title":"J Exp Med"},{"key":"R43-20231201","first-page":"5588","article-title":"Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.","volume":"8","author":"Conway","year":"1988","journal-title":"Mol Cell Biol"},{"issue":"5 suppl","key":"R44-20231201","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1097\/00003246-200205001-00008","article-title":"Endothelium: interface between coagulation and inflammation.","volume":"30","author":"Levi","year":"2002","journal-title":"Crit Care Med"},{"key":"R45-20231201","first-page":"580","article-title":"Vascular toxicity associated with antineoplastic agents.","volume":"19","author":"Doll","year":"1992","journal-title":"Semin Oncol"},{"key":"R46-20231201","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E","article-title":"Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome by protein A immunoadsorption of plasma.","volume":"71","author":"Snyder","year":"1993","journal-title":"Cancer"},{"key":"R47-20231201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V72.2.451.451","article-title":"Intravascular hemolysis and renal insufficiency after bone marrow transplantation.","volume":"72","author":"Guinan","year":"1988","journal-title":"Blood"},{"key":"R48-20231201","first-page":"339","article-title":"Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?","volume":"3","author":"Chappell","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"R49-20231201","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/ki.1989.132","article-title":"Delayed renal failure with extensive mesangiolysis following bone marrow transplantation.","volume":"35","author":"Antignac","year":"1989","journal-title":"Kidney Int"},{"key":"R50-20231201","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V77.8.1837.1837","article-title":"Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies.","volume":"77","author":"Rabinowe","year":"1991","journal-title":"Blood"},{"key":"R51-20231201","first-page":"405","article-title":"Hemolytic uremic syndrome following bone marrow transplantation.","volume":"7","author":"Juckett","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"R52-20231201","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(94)91228-9","article-title":"Haemolytic-uraemic syndrome in practice.","volume":"343","author":"Neild","year":"1994","journal-title":"Lancet"},{"key":"R53-20231201","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"R54-20231201","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R55-20231201","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R56-20231201","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China.","volume":"381","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"R57-20231201","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jth.14859","article-title":"D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.","volume":"18","author":"Zhang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R58-20231201","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","article-title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis.","volume":"506","author":"Lippi","year":"2020","journal-title":"Clin Chim Acta"},{"key":"R59-20231201","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1055\/s-0040-1710006","article-title":"Platelets in coronavirus disease.","volume":"46","author":"Brogaard Larsen","year":"2020","journal-title":"Sem Thromb Hemost"},{"key":"R60-20231201","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1055\/s-0040-1717139","article-title":"Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I.","volume":"46","author":"Favaloro","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"R61-20231201","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11739-020-02601-y","article-title":"COVID-19 coagulopathy: is it disseminated intravascular coagulation?","volume":"16","author":"Levi","year":"2021","journal-title":"Intern Emerg Med"},{"key":"R62-20231201","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jth.14854","article-title":"The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.","volume":"18","author":"Ranucci","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R63-20231201","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2020.05.018","article-title":"Tocilizumab for severe COVID-19: a promising intervention affecting inflammation and coagulation.","volume":"76","author":"Levi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R64-20231201","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccc.2019.12.004","article-title":"Coagulation disorders in hemophagocytic lymphohistiocytosis\/macrophage activation syndrome.","volume":"36","author":"Valade","year":"2020","journal-title":"Crit Care Clin"},{"key":"R65-20231201","doi-asserted-by":"crossref","first-page":"e00271","DOI":"10.1128\/mBio.00271-13","article-title":"Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.","volume":"4","author":"Gralinski","year":"2013","journal-title":"mBio"},{"key":"R66-20231201","first-page":"260","article-title":"Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy.","volume":"18","author":"Liu","year":"2005","journal-title":"Biomed Environ Sci"},{"key":"R67-20231201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12047","article-title":"Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome.","volume":"11","author":"Glas","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R68-20231201","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/rth2.12400","article-title":"Thrombosis and coagulopathy in COVID-19: an illustrated review.","volume":"4","author":"Levi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"R69-20231201","doi-asserted-by":"crossref","DOI":"10.1080\/17476348.2021.1899815","article-title":"Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy.","author":"Iba","year":"2021 March 14","journal-title":"Expert Rev Respir Med"},{"key":"R70-20231201","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis.","volume":"29","author":"Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R71-20231201","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients.","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine"},{"key":"R72-20231201","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/jth.14975","article-title":"Coagulopathy in COVID-19.","volume":"18","author":"Iba","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R73-20231201","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-0040-1712156","article-title":"Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both.","volume":"46","author":"Levi","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"R74-20231201","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R75-20231201","article-title":"Pulmonary and cardiac pathology in Covid-19:the first autopsy series from New Orleans.","author":"Fox","journal-title":"medRxiv"},{"key":"R76-20231201","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy.","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"R77-20231201","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"key":"R78-20231201","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11739-020-02394-0","article-title":"Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.","volume":"15","author":"Bazzan","year":"2020","journal-title":"Intern Emerg Med"},{"key":"R79-20231201","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19.","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"R80-20231201","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/jth.13953","article-title":"The role of ADAMTS-13 in the coagulopathy of sepsis.","volume":"16","author":"Levi","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:14:05Z","timestamp":1702923245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000571","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}